港股異動 | 恆大健康(0708.HK)大漲超13% 新能源汽車或有新進展
格隆匯2月14日丨恆大健康(0708.HK)股價強勢拉昇上漲,現大漲13.47%,報8.51港元,暫成交5016萬港元,最新總市值735.3億港元。消息上,於此前2019年恆大健康中期業績發佈會上,恆大管理層曾透露了恆大新能源汽車進展,據介紹其與科尼賽克合作的新車型將在2020年3月的日內瓦車展亮相。許家印曾表示,恆馳品牌首款車型將於2020年上半年亮相,2021年實現量產。公司附屬NEVS旗下的全資子公司也正為集團的汽車品牌“恆馳”電動汽車進行研發工作。恆大健康主要業務為國際醫院、養老及康復產業,以及高科技新能源汽車製造投資,自2018年6月佈局新能源汽車以來,恆大在新能源汽車領域投資不斷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.